Drugs / MVA-p53 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02275039 | Jan 2015 → Apr 2018 | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-p53 vaccine | “MVA-p53 vaccine” NCT02275039 ↗ |
| Action | Deplete | “kill tumor cells that express p53” NCT02275039 ↗ |
| Modality | Vaccine | “modified vaccinia virus ankara vaccine expressing p53” NCT02275039 ↗ |
| Route | Subcutaneous | “Given SC” NCT02275039 ↗ |